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OBJECTIVES: To examine the prevalence of Biologically Based Therapies (BBTs) use 
and assessment of Health Related Quality of Life (HRQoL) in a group of cancer 
patients. METHODS: The study was undertaken with 393 cancer patients at the 
oncology wards of Penang General Hospital, Malaysia. The health related quality of 
life was assessed by using European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30). RESULTS: Out of 393 
participants, 184 (46.1%) reported to use different types of Complementary and 
Alternative Medicines (CAM). Among the CAM users, 134 (72.8%) reported using 
BBTs and thus labelled as BBTs users and vice versa. Nutritional supplements such 
as vitamins, minerals, enzymes (n=139) and special diet such as herbs, animal 
products, juices (n=74) were the common type of BBTs used by patients. More than 
half of the participants were not sure of their monthly expenditures on BBTs. 
However, 26.3% reported to spend an average of 101-500Malaysian Ringgit (MYR) 
per month on these therapies. Friends and family members were the most 
common source of BBTs recommendations (75.5%). BBTs use was disclosed to the 
doctors by 42.1% of the participants. BBTs users reported better HRQoL compare to 
non BBTs users. On functional scale significant difference was observed in role 
(p=0.01) and emotional (p=0.04) scores between BBTs users and non-users. On 
symptoms scale fatigue (p=0.006), nausea &vomiting (p<0.001), pain (p=0.04), 
insomnia (p=0.01) and appetite loss (p<0.001) were significantly different among 
BBTs users and non-users. No significant difference was found in Global health 
status/quality of life score between BBTs users and non-users (p=0.85). 
CONCLUSIONS: The use of biologically based therapies is common among cancer 
patients in Malaysia. HRQoL assessment reveals better quality of life of BBTs users 
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OBJECTIVES: To review European Medicine Agency approvals in oncology for 
2006-2012 to determine commonly used primary endpoints and endpoints based 
on patient reported outcomes (PROs). METHODS: The initial identification of 
oncology approvals was conducted in PROLabels (2006-2012). This was 
supplemented with a review of European Assessment Reports, Summary of 
Product Characteristics, Procedural Steps, Summary of the European Public 
Assessment Report and Scientific Discussion documents. RESULTS: There were 8 
approvals in neoplasms, 3 in anemia, 4 in pain, 1 in nausea and vomiting, 1 in 
paroxysmal hemoglobinuria. Primary endpoints for approval of oncology drugs 
included progression free survival (n=5), endpoints based on pain intensity (n=3), 
overall survival (n=2), hemoglobin stabilization/blood transfusion requirement 
(n=1), no emesis/no use of rescue medications (n=1), lesion clearance (n=1). PRO 
measure used included the BPI-SF, MPQ, FACIT-F, FACIT-An, FACT-L, EORTC-
QLQ-C30, Pain NRS, nausea VAS, TSQM, Trial Outcomes Index and an unreported 
measure. The type of PRO endpoints in the approved labeling included: Pain 
(n=7), HRQOL (n=6), fatigue (n=3), emetic episodes/use of rescue medications 
(n=1), treatment satisfaction (n=1). CONCLUSIONS: Manufacturers frequently 
supplement primary endpoints with supplemental PRO data. European approvals 
include labeling information that is often not permitted by the FDA such as 
improved HRQOL.  
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OBJECTIVES: Although Hispanics are the fastest growing ethnic group and 
cancer the second leading cause of death among Hispanics in the U.S., few 
studies have documented the impact of cancer diagnosis on the quality of life 
and caregiving experiences of Hispanic family caregivers. The aim of this study 
was to explore the influence of culture on the caregiving experiences and 
perceptions of QOL among Mexican-American (MA) family caregivers of adults 
with advanced cancer. METHODS: This qualitative descriptive study was 
conducted in the ambulatory care setting of an NCI-Comprehensive cancer care 
center in the United States. Twenty MA family caregivers of patients with 
advanced cancer participated in qualitative interviews. Thematic analysis of the 
interviews and the conceptual model of Quality of Life Well-being developed by 
Ferrell, Wisdom, and Wenzel (1989) were used to characterize the caregiving 
experience and the effects of caregiving on QOL of MA cancer family caregivers. 
RESULTS: In general, the caregiving experience and the meaning of QOL 
centered on spiritual or religious beliefs and practices, concern for providing the 
best home care, inclusion of extended family support, and the desire to fulfill 
cultural role and responsibility expectations. Overall, MA caregivers emphasized 
that their caregiving experience had more positive than negative outcomes. The 
caregiver’s overall QOL was primarily affected by the patient’s advanced disease, 
the consequences of the cancer treatment and its related side effects, and the 
patient’s emotional/psychological needs. Secondarily, the caregiver’s overall 
perception of quality of life was affected by their physical, social, emotional and 
spiritual needs. CONCLUSIONS: These findings provide insight into the cultural 
dimension inherent in the caregiving experience and perceptions of QOL of MA 
cancer family caregivers. It is imperative to recognize the influence of culture in 
developing culturally relevant interventions specifically designed to reduce the 
burden of cancer and improve overall caregiver QOL.  
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OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show 
improvements in health-related quality of life (HRQoL). Castration-Resistant 
Prostate Cancer (CRPC) is a chronic disease with high importance for patient 
HRQoL. The objective of this study was to review, analyze, and understand 
trends in the PRO instruments used in patients with CRPC. METHODS: A 
systematic literature search for CRPC randomized controlled trials (RCTs) with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, 
interventions, year, PRO instrument, and results for PROs. Analysis was 
conducted to identify trends in commonly used PRO instruments and categorize 
results as positive, neutral or negative. RESULTS: Ten RCTs with a total of 5797 
patients were identified. In these studies there were 13 different PROs 
instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, EQPR25, 
FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most 
commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 
(used in 1,091 patients). Six studies reported positive results with improvement 
in quality of life symptoms (QoL) versus comparator treatments. Fours studies 
reported results with deterioration in (QOL). Three studies reported 
improvement in pain scores. CONCLUSIONS: Patients with CRPC have relatively 
longer survival and hence QoL is an important consideration for these patients. 
PRO instruments such as FACT-P and EQC-30 have been commonly used to 
generate evidence to show which therapies improve patient QoL.  
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OBJECTIVES: Despite a shift towards consideration of pain as a focus of 
treatment rather than a symptom to be managed, the introduction of new 
products for pain has been detrimentally affected by reimbursement frameworks 
that are unlikely to support decisions that favour patient access. This situation 
exists despite public support for effective pain management, particularly within 
the palliative care setting. This study aims to identify the mechanisms that limit 
the available therapeutic options in pain management and to suggest potential 
alternative approaches to be considered. METHODS: The study involved 
interviews with 30 interviewees in the US, France, Germany and the UK, 
including national level HTA influencers, medical directors, influencers on 
hospital formularies and product use, palliative medicine consultants, 
anaesthesiologists and oncologists. Interviews focused on the challenges of 
securing a favourable reimbursement status and a commercially viable price in a 
pain indication, as well as the difference between treatment guidelines and 
clinical practice. The success (or not) of market access for 4 selected pain 
products was also assessed based upon a set of criteria set out in the poster. The 
organisational structures for delivery of pain services were also considered. 
RESULTS: New pain products struggle to secure uptake in both the US and EU. 
Countries adopting a model that attaches the achievable price level with the 
level of additional clinical benefit demonstrated (France, Germany) are reluctant 
to consider favourable assessment versus established cheap products. The 
absence of life extension and common existence of pain in late stage disease 
means countries adopting a cost-effectiveness model (UK) are methodologically 
unsuited to evaluation of such products. US payers are likely to place restrictive 
prior authorisation requirements on products while cheap options exist. 
CONCLUSIONS: Patient access to new pain therapies is significantly limited by 
reimbursement policy in the US and EU, including in instances where the 
product has a recognised clinical benefit.  
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OBJECTIVES: To explore the prevalence, diagnosis & treatment protocol of breast 
cancer in patients treated at Bahawalpur institute of nuclear medicine and 
oncology (BINO). METHODS: A retrospective study was carried out on the data 
from the treatment records of patients (n=300). Patient age, education status, 
involved breast, type & stage of disease at diagnosis, socioeconomic status of 
patients & metastasis in patients as well as the treatment protocols was 
evaluated. Statistical tools were applied for analysis. RESULTS: The mean age of 
patients was 48±15 & 92% patients were illiterate. Infiltrating ductal carcinoma 
(IDC) 96% was the most common type of breast cancer found in population and 
were mostly diagnosed at Grade 3 (69%). Most of the patient had carcinoma of 
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right breast (53%) while about 43% had of left breast. Patients with breast cancer 
were mostly married (99%) & patients were belonging to poor socioeconomic 
status. Diagnostic tests performed for most of the cancer patients were 
mammography, biopsy, USG, X-ray & MUGA & bone scan and about 60% of the 
population had undergone mastectomy. CONCLUSIONS: Infiltrating ductal 
carcinoma (96%) was found the most common type of breast cancer in southern 
Punjab. The socioeconomic status of the patients might affect the prevalence of 
breast cancer in patients  
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OBJECTIVES: To evaluate the prevalence and patterns of CAM use among cancer 
patients in Malaysia. In addition, the study focuses on the perceived 
effectiveness of CAM over conventional therapies, information seeking 
behaviour and CAM disclosure to health care providers. METHODS: The study 
was designed as a questionnaire based, cross sectional analysis. A prevalence 
based sample of 393 cancer patients attending the oncology clinics at Penang 
General Hospital was hereby selected for the study. Adult patients (18 years old), 
having diagnosed with cancer (any type), able to read or understand Malay 
(national language of Malaysia) or English language were recruited between 
August to November 2011. RESULTS: Overall, 393 questionnaires were completed 
and included in the analysis, showing that 46.1% of cancer patients had used 
CAM, with most (57.6%) believing that CAM therapies assisted the body’s natural 
forces to heal. CAM usage was significantly associated with gender (P=0.021), 
level of education (P=0.001), employment status (P=0.02) and monthly income 
(P<0.001). Among the frequently used CAM were biologically-based therapies 
including nutritional supplements (used by 75.5% of the participants). Friends 
and family members were the most common source of CAM information (for 
75.5% of the participants). Only 13% reported side effects from using CAM. CAM 
use disclosure to the doctors was 43%; however, doctors had specifically asked 
about CAM use in 33.4% of the cases. The most common reason given for non-
disclosure was ‘it is not important for the doctors to know about CAM use  
(34.2%). CONCLUSIONS: Cancer management and treatment requires compliance 
to effective therapies at early stages. Health care providers should engage cancer 
patients in an open non-judgmental dialogue to ascertain better understanding 
of cancer and its treatment options.  
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OBJECTIVES: Current international guidelines for breast cancer follow-up are not 
specific to individual risk of local regional recurrences. Instead, for personalised 
follow-up it is required to have more precise estimates of local regional 
recurrence probability as a function of time. The objective of this study is to 
identify prognostic factors, and to quantify individualized and time dependent 
local regional recurrence risk rates. METHODS: Prognostic factors for local 
regional recurrence of breast cancer were identified due to a three-step funnel 
approach, including: scoping literature review, expert consultation and stepwise 
multivariate regression analysis. Quantification of the prognostic value of each 
risk factor was performed with a regression model based on a five-year dataset 
of women diagnosed with breast cancer in the Netherlands in 2005 or 2006 
(n=17762). Six-month interval risk probabilities were derived from regression 
estimates by calculating coefficients of the prognostic factors. RESULTS: Eight 
prognostic factors were identified, including: age, tumour size, multifocality, 
gradation, adjuvant chemo-, adjuvant radiation-, hormonal therapy and triple 
negative status. Expected inter-patient variability was elucidated by average, and 
high risk example patient types with local regional, non-uniform distributed, 
recurrence risks of 5.2% and 12% over a five-year period. CONCLUSIONS: It is 
concluded that local regional recurrence risks are not distributed uniformly, and 
time depended, over the five-year follow-up period. The calculated prognostic 
value of the factors enables quantification of risks for local regional recurrences 
on six-month time intervals for the individual patient. Implicating improved 
allocation of hospital capacities and resources, local regional recurrence risk 
profiling is a first step towards tailored follow-up in breast cancer care.  
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OBJECTIVES: Appropriate use of medical imaging tests is a growing area of policy 
discussion. Quantitative methods can characterize benefits and risks of medical 
imaging tests and distinguish necessary from unnecessary utilization.  
Our objective was to assess the extent of quantitative benefit-risk analyses (BRA) 
published in medical imaging testing. METHODS: Using PubMed and the 
Cochrane Library, a computerized search was performed to identify studies 
published between January, 1979 and January, 2013. The search was limited  
to include only studies that quantified benefits and risks/harms of ionizing 
radiation imaging in screening or diagnostics. RESULTS: Seventy-eight studies 
called for the need to weigh benefits and risks associated with medical imaging 
tests but only seven studies quantified at least one benefit and one risk/harm. Of 
these, two studies reported BRA of mammography. Three studies addressed 
positron emission tomography (PET): two studies assessed BRA of full body  
PET in cancer screening and one study assessed BRA of PET in lung cancer 
diagnosis. The remaining two studies reported BRA of computed tomography 
colonography. Of the four studies published in English, benefits were reported in 
terms of life extension, and harms were reported as radiation-related cancer risk 
or loss of life-years. Studies used micro-simulation modeling, epidemiological or 
survey methods. CONCLUSIONS: This review illustrates that a gap exists 
between the number of studies referring to the need for assessing the benefit-
risk balance in medical imaging and the number of studies measuring that 
balance. Challenges such as translating imaging information into impacts  
on patient outcomes, multiple applications of imaging tests, difficulty in 
measuring harms from ionizing radiation and additional procedures spurred 
from false positive results hinder the necessary movement toward using 
quantitative methods. Meeting the goals of patient-centered outcomes and 
understanding areas of appropriate use, overutilization and underutilization 
requires further development of a framework for quantitative BRA of medical 
imaging tests.  
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OBJECTIVES: Willingness to pay (WTP) for new health technologies may vary 
between interventions that prolong patients' life-expectancy and interventions 
that only improve patients' quality of life (QoL), and among different types of 
disease. We determined how Israeli oncologists and family physicians value life-
prolongation vs. QoL-enhancing outcomes attributable to cancer and congestive 
heart failure (CHF) interventions. METHODS: We presented physicians with two 
scenarios involving a hypothetical patient with metastatic cancer expected to 
survive 12-months with current treatment. In a life-prolongation scenario, we 
suggested that a new treatment increases survival at an incremental cost of 
$50,000 over the standard of care. Participants were asked what minimum 
improvement in median months of survival the new therapy would need to 
provide for them to recommend it over standard of care. In the QoL-enhancing 
scenario, we asked the maximum WTP for an intervention that leads to the same 
survival as the standard treatment, but increases patient's QoL from 50 to 75 (on 
a 0-100 scale). We replicated these scenarios substituting a patient with CHF 
NYHA Class IV instead of metastatic cancer. We derived the incremental cost-
effectiveness ratio (ICER) per QALY gained threshold implied by each response. 
RESULTS: In the life-prolongation scenario the median cost-effectiveness 
thresholds implied by oncologists were $150,000/QALY and $100,000/QALY for 
cancer and CHF respectively. Median cost-effectiveness thresholds implied by 
family physicians were $50,000/QALY regardless the disease type. WTP for the 
QoL-enhancing scenarios was $60,000/QALY and did not differ by physicians' 
specialty or disease type. CONCLUSIONS: Our findings suggest that family 
physicians value life-prolonging and QoL-enhancing interventions roughly 
equally, while oncologists value interventions that extend survival more highly 
than those that only improve QoL. These findings may have important 
implications for coverage and reimbursement decisions of new technologies.  
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OBJECTIVES: To understand relative price differential for cancer drugs in the U.S. 
and the U.K.. Develop implications for pricing strategy and patient access for 
cancer drugs. METHODS: Ten branded cancer drugs were selected and their 
prices for similar dose and packaging were compared in the U.S. and the U.K. 
Prices were analyzed for the end of 2011 and 2012. Historical exchange rates 
were used to convert British pounds to US dollars. Relative price discount was 
calculated for all selected cancer drugs. KOLs and payers were interviewed to 
understand current and future implications of this price differential. RESULTS: 
The median price discount for selected ten branded cancer drugs in the UK 
versus the United States was ~50%. The range of discount for 10 branded cancer 
drugs was 27%-61%. The price discount for oral small molecule drugs was higher 
than for biologics (55% vs. 45%). Since the U.K. is one of the few remaining free 
pricing markets in Europe, other European markets are likely to have even higher 
discounts relative to the prices in the U.S.. Due to rising coinsurance of specialty 
products, U.S. cancer patients bear significantly higher costs than patients in the 
UK. KOL and payer interviews suggest U.S. pricing trends for cancer drugs are 
unlikely to be sustained at this level in the future. CONCLUSIONS: U.S. cancer 
drug prices are significantly higher than the prices in the U.K. This price 
differential is unlikely to be sustained in the future.  
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